D.-W. Kim

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Neha Shah, D.-W. Kim, Hagop M. Kantarjian et al. · Haematologica · 2010 · 242 citations · Full text

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

S.-E. Lee, Soo Young Choi, Ho Young Song et al. · Haematologica · 2016 · 163 citations · Full text

Imatinib Discontinuation, Imatinib Therapy, Translational Medicine +15

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Franck E. Nicolini, A. R. Ibrahim, Simona Soverini et al. · Haematologica · 2013 · 78 citations · Full text

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

S.-H. Kim, Hari Menon, Saengsuree Jootar et al. · Haematologica · 2014 · 67 citations · Full text

Hematological Malignancy, Chronic Myeloid Leukemia, Oncology +11

Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia

J.-H. Yoon, Ho‐Young Yhim, Jae‐Yong Kwak et al. · Annals of Oncology · 2016 · 60 citations · Full text

Hematological Malignancy, Medicine, Hematology +7